AI-driven clinical decision support to reduce hospital-acquired blood clots
Official title: AI-driven Clinical Decision Support to Reduce Hospital-Acquired Venous Thromboembolism
Run by Vanderbilt University Medical Center · NCT06939803 · Data updated 2026-11-12
This project will test whether an automated AI tool that flags hospitalized adults at risk can help clinicians prevent hospital-acquired blood clots at Vanderbilt hospitals.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 2236 (estimated) |
| Sponsor | Vanderbilt University Medical Center Academic / other |
| Locations | 1 site (Nashville, Tennessee) |
| Status | Recruiting |
| Started | December 17, 2025 |
| Main results expected | December 16, 2026 |
| Study ends | March 31, 2027 |
| Registry record updated | February 13, 2026 |
| Trial ID | NCT06939803 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adult inpatients at the listed Vanderbilt hospitals who are not currently receiving thromboprophylaxis and have no contraindication to prophylaxis.
✕Probably not a fit
Patients already on appropriate blood-clot prevention, those with contraindications to prophylaxis, or patients admitted outside the Vanderbilt system are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The VTE-AI randomized trial embeds an automated risk model into the electronic health record and randomizes inpatients to receive AI-driven clinical decision support alerts versus usual care. The VTE-AI algorithm computes admission and daily risk scores without clinician input and prompts clinicians to reconsider thromboprophylaxis when no orders exist and there are no contraindications. The primary outcome is the incidence of hospital-acquired venous thromboembolism during the hospital stay across Vanderbilt's urban and rural hospitals. The trial enrolls adult inpatients admitted to Vanderbilt University Medical Center and participating affiliated hospitals with no prespecified exclusions.
Why it matters
Potential benefit: If successful, the tool could lower the number of hospital-acquired blood clots, reduce complications and deaths, and decrease related healthcare costs.
How similar studies have gone: Previous prognostic models for HA-VTE have shown mixed performance, and while the VTE-AI score was retrospectively validated by the Vanderbilt team, randomized evidence that AI-driven alerts reduce HA-VTE is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inpatient admission to Vanderbilt Adult Hospital, Vanderbilt Tullahoma Harton Hospital, Vanderbilt Bedford County Hospital, or Vanderbilt Wilson County Hospital Exclusion Criteria: * None
Where it's running
-
Vanderbilt University Medical Center
Nashville, Tennessee, United States Recruiting
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.